文献速递新生儿儿童呼吸儿童心血管与肾脏

曲前列尼尔治疗新生儿先天性膈疝相关肺动脉高压

Treprostinil in Neonates with Congenital Diaphragmatic Hernia-Related Pulmonary Hypertension.
PubMed 文献 · J Pediatr · 2023-04-12

OBJECTIVE: To describe our experience with treprostinil, evaluate correlations with cardiac function, and assess for adverse effects in neonates with congenital diaphragmatic hernia-related pulmonary hypertension (CDH-PH).…

要点

  • 曲前列尼尔用于CDH-PH新生儿耐受良好,未记录严重不良反应。
  • 治疗后右心室功能指标和左心室压缩指标改善,与最终存活无关。
  • 脑钠肽水平在治疗1个月后从416.9 pg/mL降至120.5 pg/mL。

核心结论

  • 在先天性膈疝相关肺动脉高压新生儿中,曲前列尼尔给药耐受良好,并与右心室大小和功能改善相关。

主要发现

  • 曲前列尼尔中位起始年龄为19天,中位有效剂量为34 ng/kg/分钟。
  • 中位基线脑钠肽水平在治疗1个月后从416.9 pg/mL降至120.5 pg/mL。
  • 曲前列尼尔与三尖瓣环收缩期位移Z评分、右心室整体纵向应变、右心室游离壁应变、左心室偏心指数及左心室舒张和收缩 dimensions 改善相关,反映右心室对左心室压缩减轻,且与患者最终存活无关。
  • 未记录严重不良反应。

临床怎么用

  • 对于CDH-PH新生儿,可考虑使用曲前列尼尔,并监测脑钠肽及超声心动图指标评估右心室功能和左心室压缩改善情况。

局限性

  • 回顾性单中心设计,样本量有限,缺乏对照组,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe our experience with treprostinil, evaluate correlations with cardiac function, and assess for adverse effects in neonates with congenital diaphragmatic hernia-related pulmonary hypertension (CDH-PH). STUDY DESIGN: A retrospective review of a single-center prospective registry at a quaternary care children's hospital. Patients included in the study had CDH-PH treated with treprostinil between April 2013 and September 2021. Assessed outcomes were brain-type natriuretic peptide levels and quantitative echocardiographic parameters collected at baseline, 1 week, 2 weeks, and 1 month after treprostinil initiation. Right ventricular (RV) function was assessed by tricuspid annular plane systolic excursion Z-score and speckle tracking echocardiography (global longitudinal and free wall strain). Septal position and left ventricular (LV) compression were assessed by eccentricity index and M-mode Z-scores. RESULTS: Fifty-one patients were included, with an average expected/observed lung-to-head ratio of 28.4 ± 9.0%. Most patients required extra-corporeal membrane oxygenation (n = 45, 88%). Survival to hospital discharge was 31/49 (63%). Treprostinil was initiated at a median age of 19 days with a median effective dose of 34 ng/kg/minute. Median baseline brain-type natriuretic peptide level decreased from 416.9 pg/mL to 120.5 pg/mL after 1 month. Treprostinil was associated with improved tricuspid annular plane systolic excursion Z-score, RV global longitudinal strain, RV free wall strain, LV eccentricity index, and LV diastolic and systolic dimensions, reflecting less compression by the RV, regardless of ultimate patient survival. No serious adverse effects were recorded. CONCLUSIONS: In neonates with CDH-PH, treprostinil administration is well tolerated and is associated with improved RV size and function.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. De Bie FR, Avitabile CM, Flohr S, et al. Treprostinil in Neonates with Congenital Diaphragmatic Hernia-Related Pulmonary Hypertension. J Pediatr. 2023. PMID: 37059388. doi:10.1016/j.jpeds.2023.113420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。